<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="virus particle, and inhibits PLpro or 3CLpro in SARS-CoV-2. (138)" exact="Ritonavir" post="CYP3a (target unknown for coronavirus) HIV protease inhibitor. No"/>
 <result pre="polymerase Purine analog blocking viral RNA synthesis. (140) Remdesivir (141)" exact="Ribavirin" post="Guanosine nucleoside binds to nucleoside binding pocket of the"/>
 <result pre="nucleoside binding pocket of the enzyme. (133, 140, 142) Galidesivir" exact="Adenosine" post="analog, effective against Ebola, Zika, and other RNA viruses."/>
 <result pre="infections in both in-vitro and in-vivo models (138, 149â€&quot;151). This" exact="adenosine" post="analog gets incorporated into the newly synthesized viral RNA,"/>
 <result pre="effectiveness against SARS-CoV-2 (141, 155). It has been reported that" exact="chloroquine" post="immuno-modulates the host microenvironment and also interferes with the"/>
 <result pre="contact with potential COVID-19 patients, the individuals were given either" exact="hydroxychloroquine" post="or placebo as a prophylactic measure. The results revealed"/>
 <result pre="or placebo as a prophylactic measure. The results revealed that" exact="hydroxychloroquine" post="treatment had the same effect as did the placebo"/>
 <result pre="same effect as did the placebo group. The usage of" exact="hydroxychloroquine" post="resulted in minor side effects (40.1%) as compared to"/>
 <result pre="complications were observed (158). Based on the putative function of" exact="hydroxychloroquine" post="on the endosomal acidification, whereby it is presumed to"/>
 <result pre="disease. Numerous clinical trials to further explore the usage of" exact="hydroxychloroquine" post="in different combinations are in the pipeline and will"/>
 <result pre="In clinical trials, some of the combinational antiviral drugs like" exact="lopinavir" post="+ ritonavir and blockers like angiotensin receptor blocker that"/>
 <result pre="trials, some of the combinational antiviral drugs like lopinavir +" exact="ritonavir" post="and blockers like angiotensin receptor blocker that were thought"/>
 <result pre="diseases. Virol Sin. (2020) 35:12250. 10.1007/s12250-020-00204-732048130 141.WangMCaoRZhangLYangXLiuJXuMet al.. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="(2019-nCoV) in vitro. Cell Res. (2020) 30:269â€&quot;71. 10.1038/s41422-020-0282-032020029 142.OmraniASSaadMMBaigKBahloulAAbdul-MatinMAlaidaroosAYet al.." exact="Ribavirin" post="and interferon alfa-2a for severe Middle East respiratory syndrome"/>
 <result pre="508:402â€&quot;5. 10.1038/nature1302724590073 144.DevauxCARolainJMColsonPRaoultD. New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
 <result pre="Antimicrob Agents. (2020) 55:105938. 10.1016/j.ijantimicag.2020.10593832171740 145.SchrezenmeierEDÃ¶rnerT. Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol. (2020)"/>
 <result pre="Rheumatol. (2020) 16:155â€&quot;66. 10.1038/s41584-020-0372-x32034323 146.collab: ClinicalTrials.govThe Efficacy of Lopinavir Plus" exact="Ritonavir" post="and Arbidol Against Novel Coronavirus Infection. (2020). Available online"/>
 <result pre="Chem - An Asian J. (2019) 14:3962â€&quot;8. 10.1002/asia.20190084131389664 155.AguiarACCMurceECortopassiWAPimentelASAlmeidaMMFSBarrosDCSet al.." exact="Chloroquine" post="analogs as antimalarial candidates with potent in vitro and"/>
 <result pre="J Parasitol Drugs Drug Resist. (2018) 8:459â€&quot;64. 10.1016/j.ijpddr.2018.10.00230396013 156.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
 <result pre="and spread. Virol J. (2005) 2:1â€&quot;10. 10.1186/1743-422X-2-6915631631 157.SavarinoABoelaertJRCassoneAMajoriGCaudaR. Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
 <result pre="Infect Dis. (2003) 3:722â€&quot;7. 10.1016/S1473-3099(03)00806-514592603 158.BoulwareDRPullenMFBangdiwalaASPastickKALofgrenSMOkaforECet al.A randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for covid-19. N Engl J Med."/>
</results>
